Edition:
United Kingdom

Biogen Inc (BIIB.OQ)

BIIB.OQ on NASDAQ Stock Exchange Global Select Market

232.91USD
26 Mar 2019
Change (% chg)

$12.65 (+5.74%)
Prev Close
$220.26
Open
$221.92
Day's High
$233.71
Day's Low
$221.86
Volume
1,876,104
Avg. Vol
617,754
52-wk High
$388.67
52-wk Low
$216.13

Select another date:

Mon, Mar 25 2019

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen Inc said on Monday it would buy back shares worth $5 billion (3.8 billion pounds), days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

Biogen announces $5 billion buyback days after shelving Alzheimer's trials

Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

Biogen announces $5 bln buyback days after shelving Alzheimer's trials

March 25 Biogen Inc said on Monday it would buy back shares worth $5 billion, days after its stock slumped on the drugmaker's announcement to end two Alzheimer's disease trials.

Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

TOKYO Eisai Co Ltd on Friday said it has begun phase 3 clinical trials of Alzheimer's treatment BAN2401, a day after the Japanese drugmaker and U.S. partner Biogen Inc scrapped trials for another Alzheimer's drug, aducanumab.

UPDATE 2-Eisai starts phase 3 trials for second Alzheimer's drug after first's failure

* Eisai begins BAN2401 trials, confident in amyloid beta target

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion (£13.8 billion) of its value on Thursday. | Video

Biogen scraps two Alzheimer drug trials, wipes $18 billion from market value

CHICAGO/TOKYO Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday. | Video

UPDATE 5-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

CHICAGO/TOKYO, March 21 Biogen Inc and partner Eisai Co Ltd are ending two late-stage trials of their experimental Alzheimer's disease drug aducanumab, a major setback in the quest to find a treatment for the mind-wasting disease and a blow to Biogen, which lost more than $18 billion of its value on Thursday.

UPDATE 4-Biogen scraps two Alzheimer drug trials, wipes $18 bln from market value

* Analysts question Biogen growth prospects (Recasts first paragraph, adds details; updates shares)

UPDATE 3-Biogen scraps Alzheimer drug trials, wiping $17 billion off its market value

* Analysts question Biogen's growth prospects (Adds context, details, background)

Select another date: